Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: A large prospective cohort study

Breast Cancer Research

Volumn 14, Issue 3, 2012, Pages

  Ritte, Rebecca ^a   Lukanova, Annekatrin ^a   Berrino, Franco ^b   Dossus, Laure ^a   Tjønneland, Anne ^c   Olsen, Anja ^c   Overvad, Thure F ^d   Overvad, Kim ^e   Clavel Chapelon, Françoise ^f,g   Fournier, Agnès ^f,g   Fagherazzi, Guy ^f,g   Rohrmann, Sabine ^a,h   Teucher, Birgit ^a   Boeing, Heiner ⁱ   Aleksandrova, Krasimira ⁱ   Trichopoulou, Antonia ^j,k   Lagiou, Pagona ^j   Trichopoulos, Dimitrios ^l,m   Palli, Domenico ⁿ   Sieri, Sabina ^b   Panico, Salvatore ^o   Tumino, Rosario ^p   Vineis, Paolo ^q,r   Quirós, José R ^s   Buckland, Genevieve ^t   Sánchez, Maria José ^u,v   Amiano, Pilar ^v,w   Chirlaque, María Dolores ^v,x   Ardanaz, Eva ^v,y   Sund, Malin ^z   Lenner, Per ^z   Bueno de Mesquita, Bas ^aa,ab   van Gils, Carla H ^ab   Peeters, Petra H M ^q,ab   Krum Hansen, Sanda ^ac   Gram, Inger T ^ac   Lund, Eiliv ^ac   Khaw, Kay Tee ^ad   Wareham, Nick ^ae   Allen, Naomi E ^af   Key, Timothy J ^af   Romieu, Isabelle ^ag   Rinaldi, Sabina ^ag   Siddiq, Afshan ^q   Cox, David ^q   Riboli, Elio ^q   Kaaks, Rudolf ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^j UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^k HELLENIC HEALTH FOUNDATION   (Greece)

^l HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^m BIOMEDICAL RESEARCH FOUNDATION   (Greece)

ⁿ CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^o UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^p CIVILE M P AREZZO HOSPITAL   (Italy)

^q IMPERIAL COLLEGE LONDON   (United Kingdom)

^r Human Genetics Foundation   (Italy)

^s Public Health and Health Planning Directorate   (Spain)

^t CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^u ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^v CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^w BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^x Murcia Regional Health Authority   (Spain)

^y INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^z UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^aa NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^ab UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ac UNIVERSITY OF TROMSØ   (Norway)

^ad UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ae ADDENBROOKE S HOSPITAL   (United Kingdom)

^af UNIVERSITY OF OXFORD   (United Kingdom)

^ag INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BODY MASS; BREAST CANCER; BREAST TUMOR; CANCER RISK; DISEASE ASSOCIATION; ESTROGEN RECEPTOR NEGATIVE AND PROGESTERONE RECEPTOR NEGATIVE BREAST TUMOR; ESTROGEN RECEPTOR POSITIVE AND PROGESTERONE RECEPTOR POSITIVE BREAST TUMOR; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; WAIST CIRCUMFERENCE; WAIST HIP RATIO; COHORT ANALYSIS; ESTROGEN THERAPY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PREMENOPAUSE; PROSPECTIVE STUDY; RISK; RISK FACTOR;

ADIPOSITY; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BODY MASS INDEX; BREAST NEOPLASMS; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK; RISK FACTORS; YOUNG ADULT;

EID: 84860813556     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3186     Document Type: Article

References (57)

1. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat Rev Clin Oncol 2009, 6:718-730. 10.1038/nrclinonc.2009.166, 19942925.
2. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004, 13:1558-1568.
3. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007, 25:4772-4778. 10.1200/JCO.2007.12.2747, 17876012.
4. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
5. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65. 10.1186/bcr2124, 2575538, 18662380.
6. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis. Int J Cancer 2009, 124:698-712. 10.1002/ijc.23943, 18988226.
7. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol 2009, 169:1251-1259. 10.1093/aje/kwp036, 2727208, 19318616.
8. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev 2003, 12:1053-1060.
9. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004, 96:218-228. 10.1093/jnci/djh025, 14759989.
10. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304:1684-1692. 10.1001/jama.2010.1500, 20959578.
11. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997, 350:1047-1059.
12. Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004, 13:220-224. 10.1158/1055-9965.EPI-03-0301, 14973094.
13. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, Stefanick ML, McTiernan A. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002, 13:741-751. 10.1023/A:1020239211145, 12420953.
14. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjonneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D, Tumino R, Panico S, Sacerdote C, Krogh V, Peeters PH, Bueno-de-Mesquita HB, Lund E, Ardanaz E, Amiano P, Pera G, Quiros JR, Martinez C, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 2004, 111:762-771. 10.1002/ijc.20315, 15252848.
15. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997, 26(Suppl 1):S6-14.
16. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A, Clavel-Chapelon F, Thiebaut A, Wahrendorf J, Boeing H, Trichopoulos D, Trichopoulou A, Vineis P, Palli D, Bueno-de-Mesquita HB, Peeters PH, Lund E, Engeset D, Gonzalez CA, Barricarte A, Berglund G, Hallmans G, Day NE, Key TJ, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002, 5:1113-1124. 10.1079/PHN2002394, 12639222.
17. Haftenberger M, Lahmann PH, Panico S, Gonzalez CA, Seidell JC, Boeing H, Giurdanella MC, Krogh V, Bueno-de-Mesquita HB, Peeters PH, Skeie G, Hjartaker A, Rodriguez M, Quiros JR, Berglund G, Janlert U, Khaw KT, Spencer EA, Overvad K, Tjonneland A, Clavel-Chapelon F, Tehard B, Miller AB, Klipstein-Grobusch K, Benetou V, Kiriazi G, Riboli E, Slimani N. Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2002, 5:1147-1162. 10.1079/PHN2002396, 12639224.
18. Spencer EA, Appleby PN, Davey GK, Key TJ. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr 2002, 5:561-565. 10.1079/PHN2001322, 12186665.
19. Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, Hemon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw KT, Olsen A, Tjonneland A, Rodriguez L, Sanchez MJ, Etxezarreta PA, Ardanaz E, Tormo MJ, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011, 128:144-156. 10.1002/ijc.25314, 20232395.
20. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.
21. McCann J. Better assays needed for hormone receptor status, experts say. J Natl Cancer Inst 2001, 93:579-580. 10.1093/jnci/93.8.579, 11309431.
22. Layfield LJ, Gupta D, Mooney EE. Assessment of Tissue Estrogen and Progesterone Receptor Levels: A Survey of Current Practice, Techniques, and Quantitation Methods. Breast J 2000, 6:189-196. 10.1046/j.1524-4741.2000.99097.x, 11348363.
23. Flowers JL, Burton GV, Cox EB, McCarty KS, Dent GA, Geisinger KR, McCarty KS. Use of monoclonal antiestrogen receptor antibody to evaluate estrogen receptor content in fine needle aspiration breast biopsies. Ann Surg 1986, 203:250-254. 10.1097/00000658-198603000-00005, 1251085, 3954477.
24. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987, 8:138-140.
25. Li CI, Malone KE, Daling JR. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control 2006, 17:695-703. 10.1007/s10552-005-0001-7, 16633917.
26. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, Day NE. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2003, 6:407-413.
27. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995, 51:524-532. 10.2307/2532940, 7662841.
28. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995, 72:511-518. 10.1038/bjc.1995.364, 2033978, 7640241.
29. Tarone RE, Chu KC. The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States). Cancer Causes Control 2002, 13:7-14. 10.1023/A:1013960609008, 11899120.
30. Yasui Y, Potter JD. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 1999, 10:431-437. 10.1023/A:1008970121595, 10530614.
31. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001, 92:37-45. 10.1002/1097-0142(20010701)92:1<37::AID-CNCR1289>3.0.CO;2-F, 11443607.
32. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007, 9:R6. 10.1186/bcr1639, 1851385, 17239243.
33. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002, 76:27-36. 10.1023/A:1020299707510, 12408373.
34. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005, 20:2052-2060. 10.1093/humrep/dei043, 15932918.
35. Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 2004, 6:240-245. 10.1186/bcr938, 1064085, 15535853.
36. Jordan VC. The ups and downs of the estrogen receptor. J Clin Oncol 2003, 21:3-4. 10.1200/JCO.2003.10.008, 12506162.
37. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE. Control of mammary stem cell function by steroid hormone signalling. Nature 2010, 465:798-802. 10.1038/nature09027, 20383121.
38. Harris HR, Willett WC, Terry KL, Michels KB. Body fat distribution and risk of premenopausal breast cancer in the Nurses' Health Study II. J Natl Cancer Inst 2011, 103:273-278. 10.1093/jnci/djq500, 3107569, 21163903.
39. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski-Wende J, Kuller LH, ms-Campbell LL, Lane D, Vitolins M, Kabat GC, Rohan TE, Li CI. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011, 20:454-463. 10.1158/1055-9965.EPI-10-0974, 3064558, 21364029.
40. John EM, Sangaramoorthy M, Phipps AI, Koo J, Horn-Ross PL. Adult body size, hormone receptor status, and premenopausal breast cancer risk in a multiethnic population: the San Francisco Bay Area breast cancer study. Am J Epidemiol 2011, 173:201-216. 10.1093/aje/kwq345, 3011952, 21084558.
41. Hankinson SE. Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis 2005, 24:3-15.
42. Key TJ, Allen NE, Verkasalo PK, Banks E. Energy balance and cancer: the role of sex hormones. Proc Nutr Soc 2001, 60:81-89. 10.1079/PNS200068, 11310427.
43. Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 2010, 66:33-38. 10.1016/j.maturitas.2010.01.019, 20181446.
44. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006, 98:1406-1415. 10.1093/jnci/djj376, 17018787.
45. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quiros JR, Roddam A, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005, 97:755-765. 10.1093/jnci/dji132, 15900045.
46. Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P, Magnusson C. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006, 15:2482-2488. 10.1158/1055-9965.EPI-06-0489, 17164374.
47. Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011, 103:296-305. 10.1093/jnci/djq527, 3039726, 21278356.
48. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008, 26:1260-1268. 10.1200/JCO.2007.13.4338, 2346534, 18323549.
49. Tjonneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Mellemkjaer L. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 2004, 100:2328-2337. 10.1002/cncr.20250, 15160335.
50. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004, 101:1490-1500. 10.1002/cncr.20499, 15378477.
51. Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, Deapen D, Bernstein L, Ursin G. Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev 2010, 19:2366-2378. 10.1158/1055-9965.EPI-10-0162, 2936672, 20699377.
52. Magne N, Toillon RA, Castadot P, Ramaioli A, Namer M. Different clinical impact of estradiol receptor determination according to the analytical method: A study on 1940 breast cancer patients over a period of 16 consecutive years. Breast Cancer Res Treat 2006, 95:179-184. 10.1007/s10549-005-9065-z, 16317583.
53. Chebil G, Bendahl PO, Idvall I, Ferno M. Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer - clinical associations and reasons for discrepancies. Acta Oncol 2003, 42:719-725. 10.1080/02841860310004724, 14690157.
54. Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 2011, 29:2978-2984. 10.1200/JCO.2010.32.9706, 21709197.
55. Hede K. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst 2008, 100:836-7. 844, 10.1093/jnci/djn200, 18544732.
56. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
57. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329. 10.1093/annonc/mdp322, 2720818, 19535820.